PubMed:21300721 / 124-796 JSON TXT

Annnotations TAB JSON ListView MergeView

Id	Subject	Object	Predicate	Lexical cue
SS1_21300721_2_0	31-63	expanded	denotes	human Ether-à-go-go-related gene
SS2_21300721_2_0	65-69	abbr	denotes	hERG
SS1_21300721_2_1	169-187	expanded	denotes	Torsade-de-Pointes
SS2_21300721_2_1	189-192	abbr	denotes	TdP
AE1_21300721_2_0	SS1_21300721_2_0	SS2_21300721_2_0	abbreviatedTo	human Ether-à-go-go-related gene,hERG
AE1_21300721_2_1	SS1_21300721_2_1	SS2_21300721_2_1	abbreviatedTo	Torsade-de-Pointes,TdP

Id	Subject	Object	Predicate	Lexical cue
T1	169-187	HP_0001664	denotes	Torsade-de-Pointes
T2	194-205	HP_0011675	denotes	arrhythmias

Id	Subject	Object	Predicate	Lexical cue
T1	0-672	OBJECTIVE	denotes	The level of inhibition of the human Ether-à-go-go-related gene (hERG) channel is one of the earliest preclinical markers used to predict the risk of a compound causing Torsade-de-Pointes (TdP) arrhythmias. While avoiding the use of drugs with maximum therapeutic concentrations within 30-fold of their hERG inhibitory concentration 50% (IC(50)) values has been suggested, there are drugs that are exceptions to this rule: hERG inhibitors that do not cause TdP, and drugs that can cause TdP but are not strong hERG inhibitors. In this study, we investigate whether a simulated evaluation of multi-channel effects could be used to improve this early prediction of TdP risk.